• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndrome-A Follow-up of 2 Years.抗磷脂综合征伴严重血小板减少症患者广泛性深静脉血栓形成的治疗挑战——一项为期2年的随访研究
Int J Angiol. 2019 Jul 30;33(1):66-69. doi: 10.1055/s-0039-1693996. eCollection 2024 Feb.
2
An unusual case of dengue shock syndrome complicated by ilio-femoral deep vein thrombosis; a case report.罕见登革热休克综合征合并髂股深静脉血栓形成病例报告
BMC Infect Dis. 2020 May 12;20(1):335. doi: 10.1186/s12879-020-05062-y.
3
Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome.以抗β2糖蛋白-1抗体为病因的抗磷脂综合征导致SAPHO综合征患者反复出现胫静脉血栓形成
Acta Dermatovenerol Croat. 2016 Dec;24(4):305-306.
4
A Rare Case of Simultaneous Evans Syndrome and Primary Antiphospholipid Syndrome.Evans综合征与原发性抗磷脂综合征并存的罕见病例
Cureus. 2020 Feb 1;12(2):e6845. doi: 10.7759/cureus.6845.
5
Thrombocytopenia in high-risk patients with antiphospholipid syndrome.抗磷脂综合征高危患者的血小板减少症。
J Thromb Haemost. 2018 Mar;16(3):529-532. doi: 10.1111/jth.13947. Epub 2018 Jan 25.
6
May-Thurner syndrome, a diagnosis to consider in young males with no risk factors: a case report and review of the literature.梅-图二氏综合征,一种在无风险因素的年轻男性中需考虑的诊断:一例病例报告及文献综述
J Med Case Rep. 2021 Mar 19;15(1):141. doi: 10.1186/s13256-021-02730-8.
7
Homozygous Factor V Leiden Complicated by Heparin-Induced Thrombocytopenia: A Case Report.纯合子因子V莱顿突变合并肝素诱导的血小板减少症:一例报告
J Med Cases. 2022 May;13(5):225-228. doi: 10.14740/jmc3914. Epub 2022 Apr 23.
8
A Difficult and Rare Case of Warfarin Refractory Antiphospholipid Syndrome Presenting With Catastrophic Antiphospholipid Syndrome Complicated by Gastrointestinal Bleeding.1例华法林难治性抗磷脂综合征伴灾难性抗磷脂综合征并胃肠道出血的疑难罕见病例
Cureus. 2021 Aug 11;13(8):e17106. doi: 10.7759/cureus.17106. eCollection 2021 Aug.
9
Living donor renal transplantation in patients with antiphospholipid syndrome: A case report.抗磷脂综合征患者的活体供肾肾移植:一例报告。
Medicine (Baltimore). 2016 Nov;95(46):e5419. doi: 10.1097/MD.0000000000005419.
10
Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients.儿科抗磷脂综合征的临床特征和血栓形成结局:58 例患者分析。
Clin Rheumatol. 2018 May;37(5):1295-1303. doi: 10.1007/s10067-017-3776-5. Epub 2017 Jul 26.

引用本文的文献

1
Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge.抗磷脂综合征所致严重血小板减少伴复发性广泛深静脉血栓形成病例,管理挑战
Clin Case Rep. 2025 Feb 13;13(2):e9430. doi: 10.1002/ccr3.9430. eCollection 2025 Feb.

本文引用的文献

1
Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.隐匿性阴谋家:关于血小板减少症和抗磷脂综合征的对话。
Curr Opin Rheumatol. 2019 May;31(3):231-240. doi: 10.1097/BOR.0000000000000595.
2
Anticoagulating patients with high-risk acquired thrombophilias.对伴有高危获得性血栓形成倾向的患者进行抗凝治疗。
Blood. 2018 Nov 22;132(21):2219-2229. doi: 10.1182/blood-2018-05-848697.
3
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.直接口服抗凝剂治疗的抗磷脂综合征患者血栓形成风险增加。来自国际患者水平数据荟萃分析的结果。
Autoimmun Rev. 2018 Oct;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009. Epub 2018 Aug 11.
4
Thrombocytopenia in high-risk patients with antiphospholipid syndrome.抗磷脂综合征高危患者的血小板减少症。
J Thromb Haemost. 2018 Mar;16(3):529-532. doi: 10.1111/jth.13947. Epub 2018 Jan 25.
5
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.利伐沙班与华法林治疗血栓形成性抗磷脂综合征患者(无论是否合并系统性红斑狼疮)(RAPS):一项随机、对照、开放标签的2/3期非劣效性试验。
Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5.
6
Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.在一项针对无血栓形成或产科并发症病史患者的长期随访研究中,持续性三联抗磷脂抗体阳性是首次发生血栓形成的强烈危险因素。
Lupus. 2017 Feb;26(2):163-169. doi: 10.1177/0961203316657433. Epub 2016 Jul 20.
7
Treatment of catastrophic antiphospholipid syndrome.灾难性抗磷脂综合征的治疗
Curr Opin Rheumatol. 2016 May;28(3):218-27. doi: 10.1097/BOR.0000000000000269.
8
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.利伐沙班用于抗磷脂综合征(RAPS)的方案:一项关于利伐沙班与华法林对比治疗血栓形成性抗磷脂综合征患者(无论是否合并系统性红斑狼疮)的前瞻性、随机对照II/III期临床试验。
Lupus. 2015 Sep;24(10):1087-94. doi: 10.1177/0961203315581207. Epub 2015 May 4.
9
The significance and management of thrombocytopenia in antiphospholipid syndrome.抗磷脂综合征中血小板减少症的意义及管理
Curr Rheumatol Rep. 2015 Mar;17(3):14. doi: 10.1007/s11926-014-0494-8.
10
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.达比加群酯和利伐沙班预防抗磷脂综合征血栓栓塞的失败:3例病例系列报道
Thromb Haemost. 2014 Nov;112(5):947-50. doi: 10.1160/TH14-03-0272. Epub 2014 Aug 14.

抗磷脂综合征伴严重血小板减少症患者广泛性深静脉血栓形成的治疗挑战——一项为期2年的随访研究

Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndrome-A Follow-up of 2 Years.

作者信息

Wei Lee Kai, Sule Ashish Anil

机构信息

Student Assistantship Programme, Lee Kong Chian School of Medicine, Singapore.

Department of General Medicine, Subspecialty of Vascular Medicine and Hypertension, Tan Tock Seng Hospital, Singapore.

出版信息

Int J Angiol. 2019 Jul 30;33(1):66-69. doi: 10.1055/s-0039-1693996. eCollection 2024 Feb.

DOI:10.1055/s-0039-1693996
PMID:38352633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10861292/
Abstract

Thrombocytopenia is one of the most common manifestations of antiphospholipid syndrome (APS). There is little evidence or definitive guidelines regarding the treatment of APS with thrombocytopenia. We describe a patient with APS and moderate-to-severe thrombocytopenia and the challenges of balancing anticoagulation with thrombocytopenia. A 19-year-old male patient presented with right lower limb swelling to the emergency department with a history of gradually worsening right leg swelling for 1 week and was diagnosed with right leg proximal deep vein thrombosis. Ultrasound Doppler of the right lower limb revealed complete venous thrombosis from the level of the popliteal vein to the distal superficial femoral vein. Subsequently, he was found to have triple-positive APS and moderate-to-severe immune thrombocytopenia, with a platelet count nadir of 31 × 10 to the ninth power/L. He was started on anticoagulation with warfarin. The severe thrombocytopenia was not treated with immunosuppressants and the platelets fluctuated in the range of moderate-to-severe thrombocytopenia but did not develop any rethrombotic or bleeding events. His platelets varied from 31 × 10 to the ninth power/L to 106 × 10 to the ninth power/L. This case report demonstrates that it may be safe to hold off treatment for thrombocytopenia in APS, even in cases of severe thrombocytopenia. Treatment with immunosuppressants may be instituted only when platelet levels fall below 20 × 10 to the ninth power/L or when there is clinically significant bleeding, as in primary immune thrombocytopenia.

摘要

血小板减少是抗磷脂综合征(APS)最常见的表现之一。关于APS合并血小板减少的治疗,几乎没有证据或明确的指南。我们描述了一名患有APS和中度至重度血小板减少的患者,以及在抗凝与血小板减少之间进行平衡时所面临的挑战。一名19岁男性患者因右下肢肿胀就诊于急诊科,其右腿肿胀逐渐加重已有1周病史,被诊断为右下肢近端深静脉血栓形成。右下肢超声多普勒检查显示,从腘静脉水平至股浅静脉远端存在完全性静脉血栓形成。随后,发现他患有三联阳性APS和中度至重度免疫性血小板减少,血小板计数最低点为31×10⁹/L。开始使用华法林进行抗凝治疗。严重血小板减少未用免疫抑制剂治疗,血小板在中度至重度血小板减少范围内波动,但未发生任何再血栓形成或出血事件。他的血小板计数在31×10⁹/L至106×10⁹/L之间变化。本病例报告表明,对于APS合并血小板减少,即使是严重血小板减少的情况,推迟治疗血小板减少可能是安全的。仅当血小板水平低于20×10⁹/L或出现临床上显著的出血时,才可能如原发性免疫性血小板减少症那样使用免疫抑制剂进行治疗。